Organogenesis: Organogenesis Stock Surges 54% After Q3 Revenue Beat And Guidance Raise
(RTTNews) - Organogenesis Holdings Inc. (ORGO) jumped 53.72% to $5.98, up $2.09, after reporting strong third-quarter 2025 results and revising its full-year outlook.
Read full article »
President & CEO
Gary S. Gillheeney Sr.
Organogenesis is a Massachusetts-based regenerative medicine company that develops bioactive and acellular biomaterials products to treat orthopedics and spine diseases.
Read more